According to a new market report published by Transparency Market Research “Organ Transplant Immunosuppressant Drugs Market: (By Drug Class: Calcineurin Inhibitors, Anti-proliferative Agents, mTOR Inhibitors, Antibodies, Steroids; By Transplant: Kidney, Bone Marrow, Liver, Heart, Lung, Others): Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2015 – 2023,” the global organ transplant immunosuppressant drugs market was valued at US$5.1 bn in 2014 and is expected to decline at a CAGR of – (5.0)% from 2015 to 2023, to reach an estimated value of US$3.2 bn in 2023.
Organ transplantation is a procedure wherein a healthy organ is transferred from a living or dead body into another individual’s body. It is the primary treatment option for end-stage organ failure. The process can also involve transplantation of more than one organ at a time. Immunosuppressant drugs are also known as anti-rejection drugs and prescribed after an organ transplant procedure. The objective of using immunosuppressant drugs is to lower the body’s ability to reject a transplanted organ. With increasing number of procedures of organ transplantation, the organ transplant immunosuppressant drugs market is anticipated to grow further. Additionally, rising health care expenditure, growing elderly population, and skilled expertise in performing the procedures are the other factors supporting the market growth. According to a report published by the World Health Organization (WHO) in 2013, approximately 118,127 solid organs were reported to be transplanted globally which was an increase of more than 2.5% over 2012. However, high cost of the procedure, inadequate insurance coverage, and lack of organ donors restricts the growth of the organ transplant immunosuppressant drugs market.
Geographically, the organ transplant immunosuppressant drugs market has been segmented into five major regions: North America, Europe, Asia Pacific, Latin America, and Rest of the World. North America held the largest share of the global organ transplant immunosuppressant drugs market in terms of revenue in 2014, followed by Europe. The dominance of these two regions was majorly due to more number of donors, high health care expenditure, and skilled expertise in performing the procedures. In North America, the U.S. accounted for major market share due to presence of leading manufacturers in the region and high awareness about organ transplant. North America is expected to maintain its position during the forecast period from 2015 to 2023.
Download exclusive Sample of this Report: http://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=1967
Currently, Europe accounts for the second largest share of the global organ transplant immunosuppressant drugs market owing to increasing geriatric population coupled with rising number of people diagnosed with end stage organ failure. The German Organ Transplantation Foundation (DSO) reported in 2012 that within every one million people living in Spain, 32 have donated an organ as of 2010. Germany, Spain and France witnessed highest number of organ transplants in 2013. Hence, growth in Europe would emerge from Germany, Poland, the Netherlands and other countries as organ transplant immunosuppressant drugs become more widespread in these countries.
Allergan plc, AbbVie, Inc., Bristol-Myers Squibb, GlaxoSmithKline plc, F. Hoffmann-La Roche Ltd., Pfizer, Inc., Janssen Pharmaceuticals, Astellas Pharma, Inc, Veloxis Pharmaceuticals A/S, Novartis AG, and Sanofi S.A. are the major players operating in the organ transplant immunosuppressant drugs market globally. Novartis AG was identified as the leading player in the global organ transplant immunosuppressant drugs market in 2014, accounting for a revenue share of more than 32.4%, followed by Astellas Pharma.
Transparency Market Research
90 State Street,
NY – 12207
USA – Canada Toll Free 866-552-3453